Patent ID: 8343917

Claim:
A combination of erythropoietin glycoisoforms for the reduction of mortality caused by sepsis comprising 6.2+/−2.2% of glycoisoform 4 containing 4 molecules of sialic acid per erythropoietin molecule, 14.5+/−3.0% of glycoisoform 5 containing 5 molecules of sialic acid per erythropoietin molecule, 21.4+/−2.9% of glycoisoform 6 containing 6 molecules of sialic acid per erythropoietin molecule, 21.9+/−1.7% of glycoisoform 7 containing 7 molecules of sialic acid per erythropoietin molecule, 22.3+/−2.5% of glycoisoform 8 containing 8 molecules of sialic acid per erythropoietin molecule, 13.2+/−1.2% of glycoisoform 9 containing 9 molecules of sialic acid per erythropoietin molecule and, optionally, 0.7+/−0.2% of glycoisoform 10 containing 10 molecules of sialic acid per erythropoietin molecule, wherein said combination of erythropoietin glycoisoforms has an isoelectrical point profile between 4 and 5.3 and a molecular weight profile ranging from 32 to 34 kD and wherein said erythropoietin is recombinant human erythropoietin.